[go: up one dir, main page]

AR038972A1 - Derivados de bencimidazol n3 alquilado como inhibidores de mek - Google Patents

Derivados de bencimidazol n3 alquilado como inhibidores de mek

Info

Publication number
AR038972A1
AR038972A1 ARP030100888A ARP030100888A AR038972A1 AR 038972 A1 AR038972 A1 AR 038972A1 AR P030100888 A ARP030100888 A AR P030100888A AR P030100888 A ARP030100888 A AR P030100888A AR 038972 A1 AR038972 A1 AR 038972A1
Authority
AR
Argentina
Prior art keywords
nr3r4
heteroaryl
aryl
heterocyclyl
nr5c
Prior art date
Application number
ARP030100888A
Other languages
English (en)
Inventor
Eli M Wallace
Joe P Lyssikatos
Allison L Marlow
T Brian Hurley
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of AR038972A1 publication Critical patent/AR038972A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composición farmacéutica que los contiene, junto con un vehículo y su uso como inhibidor de la actividad de MEK y para tratamiento de enfermedades hiperproliferativas, como cáncer e inflamación. Reivindicación 1: Un compuesto de la fórmula (1) y sales farmacéuticamente aceptadas, prodrogas y solvatos en donde: R1, R2, R9 y R10 se seleccionan independientemente de H, halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -OR3, -C(O)R3, -C(O)OR3, NR4C(O)OR6, -OC(O)R3, -NR4SO2R6, -SO2NR3R4, -NR4C(O)R3, -C(O)NR3R4, NR5C(O)NR3R4, -NR5C(NCN)NR3R, -NR3R4, o alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-10, cicloalquilalquilo C3-10, -S(O)j(alquilo C1-6), -S(O)j(CR4R5)m-arilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, -O(CR4R5)m-arilo, -NR4(CR4R5)m-arilo, -O(CR4R5)m-heteroarilo, NR4(CR4R5)m-heteroarilo, -O(CR4R5)m-heterociclilo, o -NR4(CR4R5)m-heterociclilo, en donde cada porción alquilo, alquenilo, alquinilo, cicloalquilo, arilo, heteroarilo, y heterociclilo es optativamente sustituida con 1 a 5 grupos seleccionados independientemente de oxo, halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR4SO2R6, -SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -NR3R4,-NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, heterociclilalquilo; R3 se selecciona de H, trifluorometilo, o alquilo C1-10, (CH2)n-cicloalquilo C3-10, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, donde cada porción alquilo, cicloalquilo, arilo, heteroarilo, y heterociclilo es optativamente sustituida con 1 a 5 grupos seleccionados independientemente de oxo, halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, NR4SO2R6, SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, NR4C(O)OR6, -NR4C(O)R3, -C(O)NR3R4, -SR3, -S(O)R3, SO2R3, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, heterociclilalquilo; R3 y R4 junto con el átomo al cual están unidos forman un anillo carbocíclico, heteroarilo, o heterocíclico de 4 a 10 miembros, cada uno de los cuales es optativamente sustituido con 1 a 3 grupos seleccionados independientemente de halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR4SO2R6, -SO2NR3R4,-C(O)R3, -C(O)OR3, -OC(O)R3 -NR4C(O)R3, -C(O)NR3R4, -SO2R3, -NR3R4, -NR5C(O)NR3R4, NR5C(NCN)NR3R4, -OR3, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo y heterociclilalquilo; R4 y R5 independientemente representan H o alquilo C1-6, o R4 y R5 junto con el átomo al cual están unidos forman un anillo carbocíclico, de heteroarilo o heterocíclico, cada uno de los cuales es optativamente sustituido con 1 a 3 grupos seleccionados independientemente de halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR4SO2R6, SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)R6, -C(O)NR3R4, -SO2R3, -NR3R4, -NR5C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, heterociclilalquilo; R6 se selecciona de trifluorometilo o alquilo C1-10, cicloalquilo C3-10, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, donde cada porción alquilo, cicloalquilo, arilo, heteroarilo o heterociclilo es optativamente sustituida con 1 a 5 grupos seleccionados independientemente de oxo, halógeno, ciano, trifluorometilo, difluorometoxi, trifluorometoxi, azido, -NR4SO2R6, SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -NR4C(O)R6, C(O)NR3R4, -SO2R3, NR3R4, -NR5C(O)NR3R4, NR5C(NCN)NR3R4, -OR3, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, heterociclilalquilo; R7 se selecciona de alquilo C1-10, cicloalquilo C3-10, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, donde cada porción alquilo, cicloalquilo, arilo, heteroarilo, heterociclilo es optativamente sustituida con 1 a 5 grupos seleccionados independientemente de oxo, halógeno, ciano, nitro, trifluorometilo, difluorometoxi, trifluorometoxi, azido , NR4SO2R6, SO2NR3R4, -C(O)R3, -C(O)OR3, -OC(O)R3, -SO2R3, -NR4C(O)OR6, NR4C(O)R3, -C(O)NR3R4, NR3R4, NR3C(O)NR3R4, -NR5C(NCN)NR3R4, -OR3, aril, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, heterociclilalquilo; W se selecciona de -C(O)OR3, -C(O)NR3R4, -C(O)NR4OR3, C(O)R4OR3, -C(O)(cicloalquilo C3-10), -C(O)(alquilo C1-10), C(O)(arilo), -C(O)(heteroarilo, y -C(O)(heterociclilo) cada uno de los cuales es optativamente sustituido con 1-5 grupos independientemente seleccionados de -NR3R4, OR3, -R3, o alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cada uno de los cuales es optativamente sustituido con 1 o 2 grupos independientemente seleccionados de -NR3R4 y -OR3;n es 0,1,2,3 o 4; m es 0,1,2,3,4,o 5, y j es 1 o 2.
ARP030100888A 2002-03-13 2003-03-13 Derivados de bencimidazol n3 alquilado como inhibidores de mek AR038972A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36416402P 2002-03-13 2002-03-13

Publications (1)

Publication Number Publication Date
AR038972A1 true AR038972A1 (es) 2005-02-02

Family

ID=28041882

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100888A AR038972A1 (es) 2002-03-13 2003-03-13 Derivados de bencimidazol n3 alquilado como inhibidores de mek

Country Status (18)

Country Link
US (2) US20030216460A1 (es)
EP (1) EP1482944A4 (es)
JP (1) JP2005526076A (es)
KR (1) KR20040098013A (es)
CN (1) CN1652792A (es)
AR (1) AR038972A1 (es)
AU (1) AU2003220202A1 (es)
CA (1) CA2478534A1 (es)
CO (1) CO5611145A2 (es)
DO (1) DOP2003000614A (es)
IL (1) IL163996A0 (es)
MX (1) MXPA04008894A (es)
PA (1) PA8569201A1 (es)
PL (1) PL378635A1 (es)
RU (1) RU2300528C2 (es)
TW (1) TW200406203A (es)
UA (1) UA76837C2 (es)
WO (1) WO2003077855A2 (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
CN101486682B (zh) * 2002-03-13 2013-08-14 阵列生物制药公司 作为mek抑制剂的n3烷基化苯并咪唑衍生物
CA2532067C (en) * 2003-07-24 2010-12-21 Stephen Douglas Barrett N-methyle-substituted benzamidazoles
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
DE602004027932D1 (de) 2003-09-22 2010-08-12 S Bio Pte Ltd Benzimidazolderivate: herstellung und pharmazeutische anwendungen
NZ547481A (en) 2003-11-19 2009-12-24 Array Biopharma Inc Heterocyclic inhibitors of mek and methods of use thereof
US7732616B2 (en) * 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
CN102786482A (zh) * 2003-11-21 2012-11-21 阿雷生物药品公司 Akt蛋白激酶抑制剂
JP2007513967A (ja) * 2003-12-11 2007-05-31 セラヴァンス， インコーポレーテッド 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
SI1802579T1 (sl) 2004-10-20 2014-03-31 Merck Serono Sa Derivati 3-arilaminopiridina
ES2330872T3 (es) * 2004-12-01 2009-12-16 Merck Serono Sa Derivados de (1,2,4)triazolo(4,3-a)piridina para el tratamiento de enfermedades hiperproliferativas.
TW201238952A (en) 2005-05-18 2012-10-01 Array Biopharma Inc Heterocyclic inhibitors of MEK and methods of use thereof
WO2007002157A2 (en) 2005-06-23 2007-01-04 Array Biopharma Inc. Process for preparing benzimidazole compounds
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
PT1934174E (pt) * 2005-10-07 2011-07-14 Exelixis Inc Azetidinas como inibidores de mek para o tratamento de doenças proliferativas
US20090030058A1 (en) * 2005-12-21 2009-01-29 Mohammed Pervez Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ATE493418T1 (de) 2006-07-06 2011-01-15 Array Biopharma Inc Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
US9303040B2 (en) 2006-07-06 2016-04-05 Array Biopharma Inc. Substituted piperazines as AKT inhibitors
RS52210B (en) 2006-07-06 2012-10-31 Array Biopharma, Inc. CYCLOPENT [D] PYRIMIDINS AS PROTEIN KINASE ACTION INHIBITORS
ZA200901009B (en) * 2006-08-21 2010-05-26 Genentech Inc Aza-benzothiophenyl compounds and methods of use
EP2069359B1 (en) 2006-08-21 2014-11-12 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
ATE531720T1 (de) * 2006-08-21 2011-11-15 Genentech Inc Aza-benzofuranylverbindungen und anwendungsverfahren dafür
JP5311673B2 (ja) 2006-12-14 2013-10-09 エグゼリクシス， インコーポレイテッド Ｍｅｋ阻害剤の使用方法
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
WO2008157179A2 (en) 2007-06-12 2008-12-24 Genentech, Inc. N-substituted azaindoles and methods of use
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
KR101650956B1 (ko) 2007-07-05 2016-08-24 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ES2533557T3 (es) 2007-07-05 2015-04-13 Array Biopharma, Inc. Pirimidil ciclopentanos como inhibidores de proteína cinasa AKT
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
ES2456966T3 (es) 2007-11-12 2014-04-24 Takeda Pharmaceutical Company Limited Inhibidores de MAPK/ERK cinasa
PT2222675E (pt) * 2007-12-19 2013-11-13 Genentech Inc 5-anilinoimidazopiridinas e métodos de utilização
NZ585306A (en) 2007-12-19 2012-05-25 Genentech Inc 8-Anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
WO2009082687A1 (en) 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines and methods of use
JP5346345B2 (ja) * 2008-01-09 2013-11-20 アレイ バイオファーマ、インコーポレイテッド Ａｋｔタンパク質キナーゼ阻害剤としての水酸化されたピリミジルシクロペンタン類
AU2009204019B2 (en) 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
EP2240494B1 (en) 2008-01-21 2016-03-30 UCB Biopharma SPRL Thieno-pyridine derivatives as mek inhibitors
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
KR20110029161A (ko) 2008-07-01 2011-03-22 제넨테크, 인크. Ｍｅｋ 키나제 억제제로서의 비시클릭 헤테로사이클
CN102137843A (zh) 2008-07-01 2011-07-27 健泰科生物技术公司 作为mek激酶抑制剂的异吲哚酮衍生物及其使用方法
NZ591498A (en) 2008-08-04 2012-09-28 Merck Patent Gmbh Novel phenylamino isonicotinamide compounds
ES2399384T3 (es) 2008-11-10 2013-04-01 Bayer Schering Pharma Ag Sulfonamido fenoxibenzamidas sustituidas
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
US8962606B2 (en) 2009-10-21 2015-02-24 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
US20120269803A1 (en) 2009-10-21 2012-10-25 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
CA2777071A1 (en) 2009-10-21 2011-04-28 Bayer Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
ES2576061T3 (es) 2010-02-25 2016-07-05 Dana-Farber Cancer Institute, Inc. Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
EA030276B1 (ru) 2010-03-09 2018-07-31 Дана-Фарбер Кэнсер Инститьют, Инк. Способы идентификации страдающих раком пациентов и лечения рака у пациентов, у которых имеется или развивается резистентность к первой терапии рака
DK2624696T3 (en) 2010-10-06 2017-03-13 Glaxosmithkline Llc Corp Service Company BENZIMIDAZOLD DERIVATIVES AS PI3-KINASE INHIBITORS
EP2632899A1 (en) 2010-10-29 2013-09-04 Bayer Intellectual Property GmbH Substituted phenoxypyridines
US9682082B2 (en) 2011-04-01 2017-06-20 Genentech, Inc. Combinations of AKT and MEK inhibitor compounds, and methods of use
KR20140025434A (ko) 2011-04-01 2014-03-04 제넨테크, 인크. Akt 억제제 화합물 및 화학요법제의 조합물, 및 사용 방법
CA2836364C (en) 2011-05-25 2021-01-26 Universite Paris Descartes Erk inhibitors for use in treating spinal muscular atrophy
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
CN103204827B (zh) 2012-01-17 2014-12-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
AU2013269809B2 (en) 2012-05-31 2017-12-21 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of Hepatocellular carcinoma (HCC) patients
MY186549A (en) 2012-10-12 2021-07-26 Exelixis Inc Novel process for making compounds for use in the treatment of cancer
MX2015013466A (es) 2013-03-21 2016-06-21 Novartis Ag Terapia de combinacion que comprende un inhibidor deb-raf y un segundo inhibidor.
WO2015038704A1 (en) 2013-09-11 2015-03-19 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Compositions for preparing cardiomyocytes
CN105384754B (zh) * 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
AR108257A1 (es) 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
WO2019096112A1 (zh) * 2017-11-14 2019-05-23 深圳市塔吉瑞生物医药有限公司 一种取代的苯并咪唑化合物及包含该化合物的组合物
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502187A (en) * 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US6469009B1 (en) * 1996-04-08 2002-10-22 Ucb, S.A. Pharmaceutical compositions for the treatment of rhinitis
US6821963B2 (en) * 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
US6506798B1 (en) * 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
BR9916904A (pt) * 1999-01-13 2001-10-30 Warner Lambert Co Benzo heterociclos e seu uso como inibidores demek
EP1144371B1 (en) * 1999-01-13 2005-11-09 Warner-Lambert Company Llc Benzenesulphonamide derivatives and their use as mek inhibitors
KR20020015376A (ko) * 1999-07-16 2002-02-27 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ｍｅｋ 억제제를 사용한 만성 통증의 치료 방법

Also Published As

Publication number Publication date
WO2003077855A2 (en) 2003-09-25
WO2003077855A3 (en) 2004-03-04
IL163996A0 (en) 2005-12-18
MXPA04008894A (es) 2005-06-20
JP2005526076A (ja) 2005-09-02
CN1652792A (zh) 2005-08-10
EP1482944A2 (en) 2004-12-08
TW200406203A (en) 2004-05-01
CO5611145A2 (es) 2006-02-28
CA2478534A1 (en) 2003-09-25
DOP2003000614A (es) 2009-09-30
PL378635A1 (pl) 2006-05-15
PA8569201A1 (es) 2004-05-21
US20030216460A1 (en) 2003-11-20
EP1482944A4 (en) 2006-04-19
RU2004127925A (ru) 2005-05-27
KR20040098013A (ko) 2004-11-18
US20060106225A1 (en) 2006-05-18
UA76837C2 (uk) 2006-09-15
RU2300528C2 (ru) 2007-06-10
AU2003220202A1 (en) 2003-09-29

Similar Documents

Publication Publication Date Title
AR038972A1 (es) Derivados de bencimidazol n3 alquilado como inhibidores de mek
AR046081A1 (es) Inhibidores heterociclicos de mek y uso de los mismos
AR038971A1 (es) Derivados de bencimidazol n3 alquilado como inhibidores de mek
AR051248A1 (es) Derivados de 3-arilamino piridina
DE69515702T2 (de) L-Tertiär-leucin-2-pyridylamid
RU2348617C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
AR044403A1 (es) Derivados de oximas y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
AR038883A1 (es) Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un metodo para prepararlos
PT83521B (pt) Processo para a preparacao de novos derivados biciclicos naftalenicos e das respectivas composicoes farmaceuticas e cosmeticas
DE69822214D1 (de) ((cyclo)alkyl substituierte)-.gamma.-aminobuttersäure derivate (=gaba analoga), deren herstellung und deren verwendung bei der behandlung von neurologischen erkrankungen
AR044152A1 (es) Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
CY1116119T1 (el) Παραγωγα ισοξαζολο-πυριδινης
ECSP055636A (es) Acidos tienil-hidroxamicos sustituidos, y su uso para tratar enfermedades asociadas con la actividad enzimatica de la histona desacetilasa
AR058885A1 (es) Compuestos de piperidina 3,5-sustituidos
RS51861B (en) Heterocyclic inhibitors of mek
ES501436A0 (es) Un procedimiento para la preparacion de fenoxialcoxifenil derivados
KR900017476A (ko) 살진균제, 및 치환된 아미노산 아미드 유도체 및 이의 제조방법
Coyne et al. Anticonvulsant semicarbazides
DE602004031338D1 (de) Isochinolin-1,3,4-trion, synthetisches verfahren und dessen verwendung
ATE159514T1 (de) Substituierte aminsäure derivate verwendbar für die behandlung von arteriosclerosis
BRPI0416564A (pt) novas prostamidas para o tratamento de glaucoma e doenças relacionadas
ATE84532T1 (de) Cyclische amide.
EA200500581A1 (ru) Производные пролина, обладающие сродством к альфа-2-дельта субъединице кальциевого канала
ATE548042T1 (de) Prostansäurederivate zur senkung des augeninnendrucks
ATE86612T1 (de) Hetera-aliphatische carboxamide.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal